CLINICAL TRIALS PROFILE FOR NATESTO

All Clinical Trials for NATESTO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02611154 ↗	Intranasal Delivery of Testosterone and Its Effect on Doping Markers	Completed	Partnership for Clean Competition	Phase 4	2015-11-18	Hypothesis: Intranasal administration of exogenous testosterone results in a characteristic profile during anti-doping testing, which is different than the profile seen when testosterone is administered into muscle, on skin or under the tongue. Objective: The investigators aim to characterize the unique steroid doping profile following administration of intranasal testosterone to healthy, active volunteer subjects.
NCT02611154 ↗	Intranasal Delivery of Testosterone and Its Effect on Doping Markers	Completed	Sports Medicine Research and Testing Laboratory	Phase 4	2015-11-18	Hypothesis: Intranasal administration of exogenous testosterone results in a characteristic profile during anti-doping testing, which is different than the profile seen when testosterone is administered into muscle, on skin or under the tongue. Objective: The investigators aim to characterize the unique steroid doping profile following administration of intranasal testosterone to healthy, active volunteer subjects.
NCT02611154 ↗	Intranasal Delivery of Testosterone and Its Effect on Doping Markers	Completed	University of Utah	Phase 4	2015-11-18	Hypothesis: Intranasal administration of exogenous testosterone results in a characteristic profile during anti-doping testing, which is different than the profile seen when testosterone is administered into muscle, on skin or under the tongue. Objective: The investigators aim to characterize the unique steroid doping profile following administration of intranasal testosterone to healthy, active volunteer subjects.
NCT02937740 ↗	Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™	Completed	Acerus Pharmaceuticals Corporation	Phase 4	2016-10-01	Multicenter study consisting of two study periods as follows: a 90-day Treatment Period, with potential extension by 30 days for those patients requiring a dose increase, as determined by the treating physician. Participants receiving 122.5mg of NATESTO (5.5 mg of testosterone) per nostril twice daily may have an increased daily dose adjustment on Day 90, based on their hypogonadism symptoms.

Clinical Trial Conditions for NATESTO

Condition Name

Condition Name for NATESTO
Intervention	Trials
Hypogonadism, Male	4
Hypogonadism	2
Aqueous Tear Deficiency	1
Erectile Dysfunction	1

Condition MeSH

Condition MeSH for NATESTO
Intervention	Trials
Hypogonadism	6
Eunuchism	4
Erectile Dysfunction	1
Infertility, Male	1

Clinical Trial Locations for NATESTO

Trials by Country

Trials by Country for NATESTO
Location	Trials
United States	20
Canada	4

Trials by US State

Trials by US State for NATESTO
Location	Trials
Florida	3
California	2
Utah	2
Rhode Island	1
Oklahoma	1

Clinical Trial Progress for NATESTO

Clinical Trial Phase

Clinical Trial Phase for NATESTO
Clinical Trial Phase	Trials
Phase 4	7
Phase 2	1
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for NATESTO
Clinical Trial Phase	Trials
Recruiting	4
Completed	3
Not yet recruiting	2

Clinical Trial Sponsors for NATESTO

Sponsor Name

Sponsor Name for NATESTO
Sponsor	Trials
Acerus Pharmaceuticals Corporation	5
University of Utah	2
University of Miami	2

Sponsor Type

Sponsor Type for NATESTO
Sponsor	Trials
Other	9
Industry	6